about
Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 DiabetesDevelopment of an Enhanced Sensitivity Bead-Based Immunoassay for Real-Time In Vivo Detection of Pancreatic β-Cell DeathEarly alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy.Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetesEndocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age.Boost for Alginate Encapsulation in Beta Cell Transplantation.Concise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes.Direct effect of glucocorticoids on glucose-activated adult rat β-cells increases their cell number and their functional mass for transplantation.Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.The endocrine pancreas. Functional morphology and histopathology.Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.Glucose, regulator of survival and phenotype of pancreatic beta cells.Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase.Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes.Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients.Immunogenicity of human embryonic stem cell-derived beta cells.Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.Purified islet cells in diabetes research.Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease:Heterogeneity in glucose sensitivity among pancreatic beta-cells is correlated to differences in glucose phosphorylation rather than glucose transport.Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients.Glucose regulates rat beta cell number through age-dependent effects on beta cell survival and proliferation.Omentum is better site than kidney capsule for growth, differentiation, and vascularization of immature porcine β-cell implants in immunodeficient rats.Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.Effects of glucose and glucagon on the fructose 2,6-bisphosphate content of pancreatic islets and purified pancreatic B-cells. A comparison with isolated hepatocytes.Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts.Heterogeneity in distribution of amyloid-positive islets in type-2 diabetic patients.Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.The beta cell population in type 1 diabetes.Accelerated Progression to Type 1 Diabetes in the Presence of HLA-A*24 and -B*18 Is Restricted to Multiple Islet Autoantibody-Positive Individuals With Distinct HLA-DQ and Autoantibody Risk Profiles.An analytical comparison of three immunoassay platforms for subpicomolar detection of protein biomarker GAD65.Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control.Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta CellsSLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipientsIncrease Functional Beta Cell Mass in Subcutaneous Alginate Capsules with Porcine Prenatal Islet Cells but Loss with Human Adult Islet CellsTransplantation of purified islet cells in diabetic BB ratsProtein kinase A-dependent phosphorylation of GLUT2 in pancreatic beta cellsRat pancreas preparation for cold storage and subsequent islet cell isolationCold-preservation of pancreatic beta cellsXenotransplantation of purified pre-natal porcine beta cells in mice normalizes diabetes when a short anti-CD4-CD8 antibody treatment is combined with transient insulin injections
P50
Q28552483-16D1174E-471B-466B-9CC5-B3F1F5FE15DBQ33569747-1CE52952-A384-47D8-8FB2-8D3C48D6AACAQ35158250-8ED5A143-1C80-4880-8DCD-9F242C58868FQ35207904-E4C5B9BB-ACB7-49CF-B5E8-76044C2EDB01Q35793478-5C82AA6C-CAC1-44B5-9AA9-C663202E1D55Q35977420-8051F52F-66C8-4B0F-A840-F181E187F99AQ36068639-28AD9017-D799-4551-B224-62AC53ED0663Q36111049-BD1AB8DE-EB9D-4EA9-A57A-2EB02D8F0651Q36209699-F8F16279-CB8A-4774-8513-E68C534AC23EQ36596542-9F2E0E8B-96F5-4152-B5EC-BB8451049A4CQ37277940-018A42CA-951D-45D1-A142-BA09244D46E2Q37403991-3111ED9A-A378-4BCF-8183-ABAB6F25F9A5Q38161556-8B2EFBD0-2556-49AE-BCA5-1CA1A07CCF36Q38682088-E036F2D3-1377-4B16-B150-BBA5396D54CEQ39096821-4897F3F3-AD03-46A6-B456-D6923290D869Q39244115-EC55A33A-BA85-407E-8460-A053410BCD6BQ39251293-11906D85-B683-4CF2-9ECF-6DB14520B653Q39435809-7B907138-E268-495B-BDB6-176265709362Q39908057-3A992A92-D955-4CC3-BFFF-BCC83876A1CBQ40873441-A148E083-A7E0-4536-B979-25879826B1C2Q41767345-B8F60C52-6B69-4E62-883D-D33312C26AAAQ41863040-25A37780-7177-48AD-B533-5B6BC4FA687AQ41865672-E82481CC-E446-4D6B-B72E-F510DAD18BCAQ42343992-CC828033-412E-47F3-9D4B-3557EC308D5AQ42847825-8CFC55CF-9F6D-4895-9299-9A338D36165FQ44707440-96E01A0E-BE40-49F8-AB0F-4335A1541035Q46169591-477338DB-F16A-49FF-B453-24470BCD98F3Q49110588-FA58E9A9-466C-44D8-926E-3EA1DC2C5572Q51832311-80601C7F-FD98-49E0-BDDD-EB96F680EB7DQ52653252-E91BE881-F987-4557-A8AE-E07E1B9FA369Q55001318-2D8E464C-FF54-45DC-BE4E-7BE6B45DAFB6Q55090214-2A4FA4DF-F0B1-4E14-92E8-43FCDF43D259Q57173754-5C43933D-8C30-45E5-A617-EEC76FCD96DCQ57177954-597D7563-ED56-40FB-8114-F0A21A1A5C1FQ57283494-B365A3C2-20DD-44A7-977E-8ABA2354FA42Q67902441-73264669-CFB8-4F7E-AFF3-88CCF0508D7CQ71070089-A94DE980-266D-4E4C-960C-E05C4E68CD82Q72537895-8C04BE83-3AFC-41F8-BDDE-D1A2900F11BAQ72705985-27F6151D-B57C-4C6A-9683-6045A4F997C0Q80152153-05032DFE-AEE6-47E8-877C-F1223DDEAB90
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Pipeleers
@ast
Daniel Pipeleers
@en
Daniel Pipeleers
@es
Daniel Pipeleers
@nl
type
label
Daniel Pipeleers
@ast
Daniel Pipeleers
@en
Daniel Pipeleers
@es
Daniel Pipeleers
@nl
altLabel
D Pipeleers
@en
prefLabel
Daniel Pipeleers
@ast
Daniel Pipeleers
@en
Daniel Pipeleers
@es
Daniel Pipeleers
@nl
P106
P166
P21
P31
P496
0000-0002-6440-2485